Global Manufacturing of CAR T Cell Therapy by Levine, Bruce L, Miskin, James, Wonnacott, Keith, Keir, Christopher

Get full text

MSC-Based Product Characterization for Clinical Trials: An FDA Perspective by Mendicino, Michael, Bailey, Alexander M., Wonnacott, Keith, Puri, Raj K., Bauer, Steven R.

Get full text

Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs by Drago, Daniela, Foss-Campbell, Betsy, Wonnacott, Keith, Barrett, David, Ndu, Adora

Get full text

Considerations for Tissue-Engineered and Regenerative Medicine Product Development Prior to Clinical Trials in the United States by Lee, Mark H., Arcidiacono, Judith A., Bilek, Anastacia M., Wille, Jeremiah J., Hamill, Caitilin A., Wonnacott, Keith M., Wells, Martha A., Oh, Steven S.

Get full text

Impact of genetically modified organism requirements on gene therapy development in the EU, Japan, and the US by Tajima, Gentaro, Huh, Seoan, Schmidt, Natalie Anne, Macdonald, Judith C., Fleischmann, Tobias, Wonnacott, Keith Merrell

Get full text

The Effects of Stress on Memory Cytotoxic T Lymphocyte-Mediated Protection against Herpes Simplex Virus Infection at Mucosal Sites by Wonnacott, Keith M, Bonneau, Robert H

Get full text

Regulation of xenogeneic porcine pancreatic islets by Arcidiacono, Judith A., Evdokimov, Evgenij, Lee, Mark H., Jones, Jeff, Rudenko, Larisa, Schneider, Bruce, Snoy, Phillip J., Wei, Cheng-Hong, Wensky, Allen K., Wonnacott, Keith

Get full text

Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy by Wonnacott, K., PhD, Lavoie, D, Fiorentino, R, McIntyre, M, Huang, Y, Hirschfeld, S

Get full text

Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson’s Disease: An Evaluation Protocol by Zeissler, Marie-Louise, Bakshi, Nikul, Bartlett, Michèle, Batla, Amit, Byrom, David, Chapman, Rebecca, Collins, Sally, Cowd, Elaine, Deeson, Eric, Ellis-Doyle, Romy, Forbes, Jodie, Gonzalez-Robles, Cristina, Jewell, Anna, Lane, Emma L., LaPelle, Nancy R., Martin, Keith, Matthews, Helen, Miller, Laurel, Mills, Georgia, Morgan, Antony, Parry, Miriam, Pushparatnam, Kuhan, Ratcliffe, Natasha, Salathiel, Dorothy, Scurfield, Paula, Siu, Carroll, Whipps, Sue, Wonnacott, Sheila, Foltynie, Thomas, Carroll, Camille B., McFarthing, Kevin

Get full text

Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative by Gonzalez-Robles, Cristina, Weil, Rimona S., van Wamelen, Daniel, Bartlett, Michèle, Burnell, Matthew, Clarke, Caroline S., Hu, Michele T., Huxford, Brook, Jha, Ashwani, Lambert, Christian, Lawton, Michael, Mills, Georgia, Noyce, Alastair, Piccini, Paola, Pushparatnam, Kuhan, Rochester, Lynn, Siu, Carroll, Williams-Gray, Caroline H., Zeissler, Marie-Louise, Zetterberg, Henrik, Carroll, Camille B., Foltynie, Thomas, Schrag, Anette

Get full text

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties by Sullivan, J P, Donnelly-Roberts, D, Briggs, C A, Anderson, D J, Gopalakrishnan, M, Xue, I C, Piattoni-Kaplan, M, Molinari, E, Campbell, J E, McKenna, D G, Gunn, D E, Lin, N H, Ryther, K B, He, Y, Holladay, M W, Wonnacott, S, Williams, M, Arneric, S P

Get full text